N
Google TrendANNA BONDAR (200+) — October 12, 2026: Tommy Paul vs Valentin Vacherot: Set 2 Winner Tennis Prediction Market
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:anna bondar200+natanael cano100+green card500+power outage near me10000+india2000+sony playstation1000+loki100+hubert hurkacz200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Armata Pharmaceuticals Se" (30 stories)

Top Headline Story

Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History
Lead StoryYahoo! Finance Canadamarkets
3d ago

Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE9YWVBFNWI4Q29DZUM2c0dUSGdFRmkwQ0FPc3JrREpJdm0xOUJxWWh1N3J2WUhjMWRlMzR1MVUxRFUyQWhIa2hodGlHMkhLdWk3TVE?oc=5" target="_blank">Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History</a>  <font color="#6f6f6f">Yahoo! Finance Canada</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+25m ago

anna bondar

October 12, 2026: Tommy Paul vs Valentin Vacherot: Set 2 Winner Tennis Prediction Market

Filter stories
100+25m ago

natanael cano

Padres de Natanael Cano rompen el silencio tras retiro del cantante: "Es por el bien de nuestro hijo"

Filter stories
500+35m ago

green card

Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows

Filter stories
10000+35m ago

power outage near me

LIVE | Atlanta weather: Power outages, tree damage remain as storm threat moves east

Filter stories

Search Results for "Armata Pharmaceuticals Se"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
PR Newswireworld

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxOeTlmSWhLZGtybGc5WlM4b21NeUxXUmRCbElYak9FT1cya3ZZdlRMcXAwVjRKaUVLQTY1Mzk5dXdtakxiN1ZmMTlpNmMwUENfVTJtdHByTm14RkVqZDJrLXhOR0NtRWxubjZYRUN4eXlaRjJickdXajVtMHVxZ2pQX2cyT2o5a3FSRllxNnFWTWhuMW9UV1lRTmg3bmNXQ2NJY1NiV240UHJERGpfMTFQSmJvbjVnOVN6T3JONjJITDJKY0RJVU1HakE0bFpvSG5ldXBvQm5nOGVvbVJ0YkJiM1RTalItT1RHcmh3TlRtU1lMdlYydUFGVmJR?oc=5" target="_blank">Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history
Yahoo Finance Singaporemarkets

Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1XWG9BME1ydXJVekZ2N2RCaFA1Vk1mQjJlY0drV2FpYkdvX3BudHFPbWJhdmw3dXJ2a0lLbGYwWXFLOTlGU21PWDkzb3dBaFpaT2c?oc=5" target="_blank">Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history</a>  <font color="#6f6f6f">Yahoo Finance Singapore</font>

Read Full StoryMore like this
Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP)
Seeking Alphageneral

Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP)

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQTXJzQXJ3Q0lianZVVG5fZ2lyd1BNUTBZZ0hfNFM0WnJwMG9FNlgwN29NbHFqSXVWeVdWMy0wWlNLTjVEYktPZjlrMWY5dkxSTlJPU1ZnZW1DRUZzVG94ZnotVmZ6dnpmaFJnZ1U2YTF0emYxZTZ1Z3dGYlYxV2lwWmFrVUs2MW04UktFbjJyT1BQcS16dFdzX0hhRkp6MWNJVDlZLTJBNTdVc2diS21BTXhMc1g?oc=5" target="_blank">Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything (NYSE:ARMP)</a>  <font color="#6f6f6f">Seeking Alpha</font>

Read Full StoryMore like this
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
PR Newswiregeneral

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

<a href="https://news.google.com/rss/articles/CBMirgJBVV95cUxOSVdGTHlxT1NBZGJ1WWZCNkxHZUZNWHJ6V19JODVObGdJQTRzS3pnT01fVVRlRDE2WVItcDVHWl9aLXdLS3VfYUY2dkdfSU1IZWxpVXdXVU42UENPek10NXFuWkprV2NBMEpXTEU4UVhMd0dwSlF2cE9uMXJNNXdXamJBMEtNZ3c5QUNRSnY4dGRURkJTcURnY1FlREY0V0Y1bGtzXzM2WDY4UEd6U0prOGNJQ0RPTmpxeU9IT0xzOENOQk1FVXo1NHlSQkVSbzJpdmRhY2I0RmZkdmlmSk1FVE5ZZ3ZSczNjc2hsbjRvaUtpSXE5YjR6U3lyd0M4c1R2Q3lmZEI3NE9sWHM1d0VlaHRlbUl5T2ZaX09wdlVlWVI5SU1ZcW9MT2FUb1ZpQQ?oc=5" target="_blank">Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
PR Newswiregeneral

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPQjRVZ0J4UTBEUXBzeW4ybGFSMlhBWG8xcGtBajVVYTZReWhsaTFYMEtLTDJWd2c3RFJOb0tfNmloU3V6eElESzBHV0RzZUxGMlpUUFpmNDhGcGNHZUFTWk9qQm45UTZNLXB5LWJidV8tMHVUYnZnOF9RTENQSjhMbVlRTGt1Mko1OUI5ckxsdEtRMzdzZnBjWlNlWHBnU1pzbEQwZzdVc00wRm5nZVJJN0doQl83MnY4c1h5OG5kYm9nSFk?oc=5" target="_blank">Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags
Seeking Alphaworld

Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNWVdlRzRIeUpJVDdDTlhDRWtNYWxBeEstZmhYTzc3cVlxUjVWOURUMzBhXzZpWkVkaGR4VUJzTnFRMGdLUmk4TkEySVBvMXJOSUtaWm5INndtVzBpakJzUFVneFpudVNiYTFIRTNibl9qa19JN09KSEZsLURFbFFQb29TSHpNU0hWREhJLW9SYWRkQWFobmx5VWJ3Y3JNMlhJSUJjSlNzRDBpSFJuOF9jVDVn?oc=5" target="_blank">Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags</a>  <font color="#6f6f6f">Seeking Alpha</font>

Read Full StoryMore like this
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Yahoo Financemarkets

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQWU5obFEybnoyeU11SWxYV2oxanhXRzBGcVM5Uk9OSEFwd25TNFVIQ0Q2RVlTVHk2akRVSTFLSmU2c1dOaXc2N1pMeW9hUmtKMGVUTXgtenJvRXdtSHVzanRLdE1UVFZGd2lOa3cwRU1xdDN3bXpWUF9tcG5GakM4eHZSd3ZmdnNGem1Val84T2ZPTlJxTFlSQk1HZ2drMEVUMlRFbHFzUQ?oc=5" target="_blank">Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
PR Newswiregeneral

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

<a href="https://news.google.com/rss/articles/CBMivAJBVV95cUxQT0hRSUxIZDZqM3VlWWdweW1UTnhkcExCT2szQ3d0M3MweU83bzZuLUdBaDU0RnpDVkVBZGI5NEJVVjdrZmVnV3k5Q3BZZXpfM1lkUklLS2dmXzh0V1l6dVFKQ2xIb2dwNXBPTjQ2VUh5ZVJKTFdVUDhMOFRkdmNoNzlrTl9Bb0l6NVZUSDhJZk0zN09ENmhReWpTbHhsUVM0R2U2bFl1X19haDFDRE8wUndDN0RmSF9GSGV0WHNfT08tbzR5UnpNZUZLOUJMOGx0UTNUOV8zaXRkVVBQQ3FPVmxyT2FDVjg5UVpIQ0tIVFFvbjVMRmw0cHdGVENKNF8yOXViY3g0N0s2bGNNQXdCcmZRSFhPOWRkZnA1RmViQ2VuOWcxdlk0cU1FellhUlBXZXRaaWZCeTJrajBt?oc=5" target="_blank">Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?
Yahoo Financemarkets

Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNU2psN1BLWWdFWk16YVp5Y1dTSWZoMTEwXzA5TjZ0MU5RRnc5NURYZjZRU25BRDJ0RVpaNTdadEQ2bG1DUHNNaTJrT0ttUlBsWGtkYkEyTkZyN3NxcEtNdmkwVEZDQlo3V2hMb0R6bFdYaWJHdUJXREJvNUctaFc0dG9iM0p1NGt3V1RITExOZ2VWbW54TGFlZ2JYWEU?oc=5" target="_blank">Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
PR Newswireworld

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxORkZxaFF2bS03cnNlc0RyZTlBU3J4R3FSNDlIME1oLVFWdDNQN1hrUDE2UzcxMGs0c2Y1MzRtMW13bzRzM3p3eEsyOERDR1JQX1dpWlJRLWU1aktFNFdONVNmS2ozU3I5SlBuakJLbjg5YVR2MHE1ZXVJSWFpRUczR2hJQ0p6dVFaOTRCYkk2bnZkX1VobkdmTUJlTVpPbFNnejNUZnN1dGp1VXkwV0JSYXpoYXBURGVuUUlYQXg4SUpOQVZPR2NKQlFIRk41dnFrei1DQWtab3NPYVB1Smc?oc=5" target="_blank">Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Yahoo Financeworld

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQaGZJbjBZRXhCbl9ud3ByRmJXNlJlc2NDQUhtUVIxeXkya21ST05rV2cza3pSSjd0NVRPdjFCS2xrMUxCbTd4Mk1RYVBVaHVXMGRmcHhHaXZTTnhEUTBqUHNqeTNhX1ZwVnRTZVJQcU5TTnRjVFhFMWJWQm1VeUxsRkQzQVJncGZ3OW1qcm1PMXN3NHlVcEVHZWZ5aWVMaHdBOHNyUGRpMER1WE5SQ0NNLWJZcjltaGM?oc=5" target="_blank">Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
PR Newswireworld

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxObks3M3l1dWZEa1lPNmUza0pQdE1CNDM3eWdlU0FFUXhDR2hFdEFvMkc1R1dWdDFvMUtMSzJqVzlhS3laUHI5UWlKTzVvcDN1TGVsaEVwNk1HTGZ2anZtc1Y3OUVacHZhaDMxWlR3RVdGS09PNEVRdmllZ3l1dHdfX2p4b19TLVZoRFpYU2NzYkNUQ2JacXZsaWpKQzFqdG13eGxxbUg1OXJzUUE0UUd5ZEZjNUhlaXdDa1hjb25NUW51Z1djVDVLcW5qaUFNZjlScmxVcnV3RVRlWnVZdklsQVNWMXdwbE1CbWlfNFlRM0dtd0RDLW9uR2FXS2dLcG9PR2tXeHlaTzJ3QUNqNE5DMExnZ2hyUEtfWm1CQlpmTQ?oc=5" target="_blank">Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
PR Newswireworld

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

<a href="https://news.google.com/rss/articles/CBMigwJBVV95cUxQNk9rOHIyYnFuNzJqWDB6VEozczk0TllsWXZHVjRvcm45eFBvUDRESGl0eEVQR1FVaEN2eVpsVS1xSmlLQ2hUVHA1Rmp0blVnaEVzYktjMVY0ejhhbHQwVXpHU091ZkdNSmlTdlJiNmxfM3ZvSWJqNkh2Nk5BWWhTY1dzSVREcFJIVkVqY3RrcVBvS1NBRWdJZnFuOVcwUEcxUGxVY2JHQlk5Q3h1ajZFeDA5NGxFZXlhaWFUcGtyN0dCQk1FS0N6OWxaalJXNFpTaVZnTEpVZnZ2bkx3ZjhQd00yRVpTQ042SzdxZFZ1Tm9oU3dlM0dId3lqaVVSeFZNckxZ?oc=5" target="_blank">Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
PR Newswireworld

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOcDhXWHRzYTdjZ1A5QldWaENCU0ZhdVhOR0I3NVlzRTBZbS00SlpWQmNJSl9qYkJkR1BVZldzMHRXUmFLOE8xamR1Wllaa1ZWYmhfUjloLUhBVThnVHNJdHVQeDEtVG1tTjU0MENSd3o0TzF5SFF2eFE3eVEtVk56U1paM3NtdEo3OFFfeDI1OFhTNGtyU2lXb2dJZEFkSlJZS2NHam9kaXVwdVNial80WkFaeGpNVkpMODZVQUItRjNaZFo2VTRNVVpDU3I5X1QwRDRnMGx2X2ZuNkhlX3c?oc=5" target="_blank">Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
PR Newswireworld

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors

<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxNSFhGTkZ4Xzc2dUpiaWFrRjJVNi05ZDQwZWlIcHJIUW1mdFpsUlQ1WEFBaVV3Snc2Rm9FZHN1UXkwRl9BT0lJaFFWcHBxaTU5X1RORUR2eVNYUGxQY18tMk8taVJmMU01ZHdNbEVBZ0NWZkU1OFhiOUo4c0Z4c0FsVzVodDVqTVctY21CVE9INTBpdG1jaGUyUm8tNi1HZzFRMEMxNGNCZ3F3TTJuVUNZMUQtVElvdHprRFl3d3FfU1BxWEMwNDFxZnBzcTk4QTlEQXA1S2NNVEdVRDNzZGZFM3B1a2pzN3JhNGN0UEhkU1V6TkhzTHRzdDNkdjNLMFlMMHptUmx1cE5mdFU3c3hXLXlYVlJCM2M?oc=5" target="_blank">Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
PR Newswiregeneral

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOd1FQWG5KZ2tTUnlCajNfcjJQUTRvMDRvOUZnQnQ0Q01aMy04Mmc2TXRaNmNha1FnUlAyVEowbGdLNzJjWjZMT3BMQ3pfbFEzRUFSVGlJdEoxQ2FaSGI3ZU1SM1gweE9EMHZJckQ2UkM2TXZmbTdzem45UEFGQVQtNV9WdUpMYnNNSVdVbTBvWDFLYWMxRWVDejlaWjNjdTF1UUp3TjJXZ21QMVNHUDZNOWZncGpXb2ZZeFN1SC1GZmx5dnFwUERoSU4xYWY3VEFqel9NNk5kM3BtTTlfWHg0WjAzdE12aGlmRlpZU29n?oc=5" target="_blank">Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
PR Newswireworld

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia

<a href="https://news.google.com/rss/articles/CBMiygJBVV95cUxPc0FmQ3pUVEVSUzY2Vkk2ZWg5WVFhRGpNcm5TLWNCTllLa2h2VE81a19NSlBraHVjTTN2a3A1Q1JlVExkeDFMc3ZkdHA3ZVBlVHEwTnhaTG1VdmtzcFZaT1lmam92RmZDbURIb1FKYzkwbHloaUV0RkZpRGJDWW9Hb2RqTm1zbkpIWi1UMWZod041allUMnBlYnQ0U20yMHB5czViOGdmZHBvTWdLSW02YUhNVHNTRF9TbXpzNERSRG5TcTR1b2d5NWpsR1ZFcnU0NFMyRVExcEpfYVVZVktxaHdrV192Q2k5LUktM0NLSWVMVXlWeGl4Tms2TWNRcEVSNWYyUmY4NF96czBjdFo2cG9UMEExcHpLRUx1VTUtVjVzb0Y2cXZ6UlVuZWZXREdsQWxCdThRdEhRM2NENkdXRkFHMHY5NDFka3c?oc=5" target="_blank">Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
PR Newswireworld

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxQdXNFeTV1YjlKYlZkQ2RVMWcybXotVTBqeGZGQXFoZWFNczhmcld5eDRmRk9SRFF5NG5fcndYdTI5ekFzOElUZXB2eU9WR1hCTjExQTZnbjRkVzR5MURmMEhWcTVKZ1dZdkhpUHJVUXFBdzMzeVhlVmZnTldvUEVWMWJQMEZrTGRuQ3JxbGhFNk5keWk2NHZYZ3hNYmc5NVlQd0hITjd5Rjl1ZWlsS0RQMUp1bXYxMDBGZ1ZCZVFfRS1aTmZUVUQtZUlSUGI0T1FsVTRpY0JiVXF2WGhXc1pPVXBvUG5EVXh4QzJRUmQ4Uk15TUwwY1FSOEJxSFMxMWJ3aVRlMmxjWVNIMUhEM0tDc2QweE5EU2Q2?oc=5" target="_blank">Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
PR Newswiretech

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

<a href="https://news.google.com/rss/articles/CBMi4AJBVV95cUxPRFRYWXJVVmlLbURRM1JGNzNqZ1ZMTnBPQmtPT1FIRHlBbmx2UFFEdWZKQUloVXVkVzc0YUljUVpaWGE1NFVkdi1PWkxDcm90NVowN21ELU12TUtCcDBubUNxZFZqcmFtYUI4MDZlSFBlRTZ2Z0RSTFp4eGRYTVJ0bVRtVlBvTEp0Y05Reko2YVF2ZWV5eV9kQkZBUWVPc3FOaWIwN2dPT1ZxTVRKQkdudGRSazVZcFh0bGRWSFZyR1hBdEdGY1VzQjBZclRCY0w4eEdDeUpyMW5mdTZOdFhKQnlPa2RUN2gzb2RXWGhyNTliX3gwd0xIWFFITFpWenE5SkRfalZkekRLdjZEV282TzctdmpZZ0lmM2RHOWpCaGRNX3JkZUN3YXh5azVOODlaN1RmaUpBbEt5ZF9ZVjRGQ3o4SkdnRzMtVHlYdWFZR3VsaUd6R0dFYXBCVUZSSHJ2?oc=5" target="_blank">Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
PR Newswireworld

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

<a href="https://news.google.com/rss/articles/CBMiugJBVV95cUxQdDQ4UkdiTFp3bm4tdmJ3aWNwTXRmWDNLaTdDcTYwa3NfTDkzVkoyWUQ1VF9maEdZNTJQWl9hekwwMmluLTBZY2sxT1E1VFdaQVBIZlBkQ0RxT1pKeERpclFfQklCRG1ucUpQelN6Z1Jsel83ejRzTmQxejZnWTlwcXFYTnlqbS1xNzY1M0tFYmpESU0xMDUxWHNhOUNNTTEtejRRRnZpQVE3R2FVSjRTakFUXzZiR0RENWZwdThwSTVBWXVqcHVUVTNjWmZneUduaS11Q0wzbnpWMXVKT1ZFZEpTNXg1Q3hLX0JsdFlNNnVLOXF2akswbm1Wemg0VWc0X0RuQ3NKckJObGVSOHE2R28zTGJtVDE5ZzJ6WDg4UmJ5elVwcWZ1QjN2UVpLRHVZYzZyNFF6dHd6QQ?oc=5" target="_blank">Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswiretech

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQMVpMdzgtdDJ1Y1VRS3BwcEtpcTBwMXNTdC1OZ0xmdjZmRXlNZTVsWU12RFphN2JMdlRUUmY2NTd0dVB0LVl5X0hIXzJQM0JkUkluRjBWeTNBdE5EZTI4ZDh0bF9HN2steWY2ZzhaNFJzWUlIQ2pqZnZObk1OY2RpbWhKam5zeGNFZmZKUXEtS3p2Zl81N1NIWUpPanViVjJwLTY2QTVnOWNsRHc2Z1Eza0pObnZnclN1NTJEZW5RNlhCb0JOblhZMWRMM3BMejQxWkpaNHhUREpZZUR4anhsZWJ0UXExTUloYTFV?oc=5" target="_blank">Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
PR Newswiregeneral

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNblZYN2hSemJIRXRnd2p0T3BWT0VwaERmUjZpVkxKb3BzS1pXczdpbUFyNG81dnN6N1ZQUl9CMWdNZjdDNWxfRlpNQm80clFDQ3BCeGFyUGV1MXBmaG8taGJuUV9PbVNscG1JYjZSTlNzVlR0c1U2SjF2LXY1VDBBUjU4ODItelFqWDRvN3BLT21kQVUwejZmUjV5MUNackhic1BHZzZiWVE0c01jbU1Qemc4MWRQc0M1YzZJQmoxc2ktVmhUQzF6ZXkyQ2w2STBRVFI4TlNB?oc=5" target="_blank">Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
PR Newswireworld

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

<a href="https://news.google.com/rss/articles/CBMirwJBVV95cUxNcVJ4dDExaG44aXNTWldkb0NFS2Z5amNNUnRyZlk2bVlmOGNpX1VSYXV5VEhZMk1pdHRIVnVJZjd0bzMyRVZRQ0t5ZV9PM2w0YUhiN1BVNWRLaXN0VVhqQ3V4b0JJdkVPSnhDZzhkWnZTU3RQTi1GN2VQX0NuZWtxZ045MldacjFVUWN3S3ZJQmx5blJKalRTWGlLR0dSVmlpakZtdW1id3dJY2twWDJlaHBuRW55bHZ0djI0WGp4QTJwTUp6eEdqeEtralhoZTVKNDE5cWhNQkRXNzJlbkgwRllFeGJnUlpUN19QcFBfbEI2MXBRMk9JVUl5SElJYXVGTW9nbm4xX2V1TDd5XzhNeVZqZ1NFRnBMY0FZaVd4VVJndmpNNGcwSVF1SUFsRGc?oc=5" target="_blank">Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
Yahoo Financegeneral

Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOVC1EY1VlSGpab2toU1ZBNnA4RTJISGRJT2ViVE9BVU5Fcjk4YjlSSjJlcUJHcUNsZWhNQndyV1BXam9CUGJfbnp0SE9TR3dvRXpCazM4NHQwRjdRY2pNU1pCSTFHcW1zUjlRR0tYbWZQS2lQWEtiWVAyTktlSWxTT0R2RnJjaDFCdW1qMGpSQWl2M2x1Vmt1a0t3U1BCdw?oc=5" target="_blank">Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
PR Newswireworld

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPc3RKdGl6dFZkOEk4YWpwai00YnZneFNDQkFoczR4WHFQcm5nRUVXZUkxWjhxdENfUXJUVUE5RGotWWRaNXhHZWx2UWxhMjR3TDRoLXI5MG85cjAxLUozQnEtTUZnWllOcXJPTnNlUUxVWXJyTjVocmxaV3B0SzFSSFBPMTFkTEZzZ2NwU0JmQ09oYWV3dG9OTG9oMXlQRV9Dc1lCTFJuYVd4Z3RhS3V0bmU1dVNfVFdVMUNtY3NTaFRNZDAwekZLblJLaDFqTEpsc25vbw?oc=5" target="_blank">Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
PR Newswirepolitics

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

<a href="https://news.google.com/rss/articles/CBMizgJBVV95cUxPUHNGTFZVMHAxdVZUREtWSWJqRzE1RkdSZWFRTHVybjdBNEl1eEg5emZIWlFhaVppMGlOdko5M1BwbERkQ2tYOXhFV3V3SWRjelpsaFZCeHJxTmo1WUdlUW03UkM5VHZ0ZTJnSjVSVmc3cUY0aHRGaElzWWZNcVBJTEhIb2ZKbzh6V2RtNlgzQ281ZFJMSlJPQlRoQzdBR1lsN1VRWllMUlplY2Z0MXRSVUJOVzFUc3V5dlh3a2VGUnI0WjFFLW1TRmQzOUxFeGh2OVVYY1o1UkhHLWFnUzVPWjlQMVoxQkcxNkVyWGNMZGhCa2dpemVKNVE4U2prWVdPbVp0QWVYZUdZSU1QeUlsbG5pVGEwNmQtLXVrQjlKdFR1RG9FM1FUWDlZZjAzdkVnNWc5ZHZmNTF5T29TRnpCeGFLa3pfNWVwQXJrMjln?oc=5" target="_blank">Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
PR Newswiretech

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

<a href="https://news.google.com/rss/articles/CBMi-gJBVV95cUxQTWpZeC1QV2pjTHpGc3dHQ2IzQk1HejlSOUNCbzFCXzI1WVV0bVJiWm9ySXhtQl9ONmoxS3hpNjg1QTVzUnozenh3U0ozVWoyejZ4bDlQY1h4VmhpcFVOVS1aZXYxVU1yaFpkcFh0dmtDVUw5OWVTdGR5T1RqMy1SNU9rcTV1UlQ2c0Eybk10MXRQdEVDZzh3ZGQ3SVI4dVlXakMtZkppQnVZYVNKZHJ1TVNFZG1INWtzUWVzUHNJMnNNd0VHZU54b1phNmYtMk1jbzJyTXFPbnRhV0xaSlIyZ2huNlZmRjRxOXpzdEdLZlhDRThPYmhJa3QxelU3OE9vTEZKYWlOMWotenJ0MGp4S25QWFpaclZ3NDNDNm9hN0NROUR3cGJ4ZFBOVjBEczN3ZWlwMFNJYWd5SmlxQ1c0cksyUHNUdk9zUTRJTXBSeG13NzAwTTNyOXU1eVhIUS1rSFBhdThEcHRHbWY3ZmZmc0hRbldacHFWZmc?oc=5" target="_blank">Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Armata Pharmaceuticals Inc. (ARMP) reports earnings
qz.comgeneral

Armata Pharmaceuticals Inc. (ARMP) reports earnings

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9NaENvTWlTd1UzQWxtNVBRUWZveFNlWmcxMUg0dEZUMEtZWXRUbDV6bkZlZW43bmlVVUhPSlJrQU1YNk1sd3RiVk9xTFV1cWRzQzlZV3pVM0toQjlzX2xrdUxpQklxa09Sem9LUnJ4QlR6S1phNi0xbkNlNjJTRnM?oc=5" target="_blank">Armata Pharmaceuticals Inc. (ARMP) reports earnings</a>  <font color="#6f6f6f">qz.com</font>

Read Full StoryMore like this
Why Is Armata Pharma Stock Gaining Monday?
Benzingatech

Why Is Armata Pharma Stock Gaining Monday?

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPV2k5TENXVG1SaF9UaGFsTkVUazVaQnBuMjlzZFhPZ1BxRm05ZGV3RUU3YjVEeGo4ZkswMUwzT2kzSS02THJXLXdwaFJOOU9NbDJVNFhfVlNNRDBqU0lHbUYxV2hEX3JqYklJWm5vZk5EdFowcklwcXFNYnVGcTg1OEdtZ3prLUNkS2U3M3lIOTl0eG1LZm41VFg0Sm1wS1k?oc=5" target="_blank">Why Is Armata Pharma Stock Gaining Monday?</a>  <font color="#6f6f6f">Benzinga</font>

Read Full StoryMore like this
"Armata Pharmaceuticals Se" — Live Google News Trends & Headlines